Clinical trials: Anti-PD-L1 Antibody
Lung Neoplasm Malignant, Interstitial Lung Disease
Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis
This is a prospective interventional open-label randomized trial. The patients treated with anti- PD-1 (programmed-death receptor type 1) or anti-PD-L1 (programmed-death ligand) antibodies in case of new acute onset interstitial…
- Trial name
- PROS-CONS (NCT04036721)
- Testing
- Prolonged glucocorticosteroid (prednisone) regimen, Short glucocorticosteroid (prednisone) regimen
- Where
- Poland
- Volunteers
- 85 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Head and Neck Cancer
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in…
- Trial name
- NCT05287113
- Testing
- Retifanlimab, INCAGN02385, INCAGN02390
- Where
- 91 sites in United States, Belgium and 12 more
- Volunteers
- 176 people
- Sponsor
- Incyte Biosciences International Sàrl
Tumors, Hematologic Malignancies
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as single agent to participants with locally…
- Trial name
- NCT01375842
- Testing
- Atezolizumab
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 661 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer, NSCLC
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent…
- Trial name
- NCT04746924
- Testing
- Tislelizumab, Ociperlimab, Pembrolizumab
- Where
- 218 sites in United States, Argentina and 17 more
- Volunteers
- 669 people
- Sponsor
- BeiGene
HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
This is a Phase Ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without…
- Conditions
- HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
- Trial name
- NCT02605915
- Testing
- Atezolizumab, Carboplatin, Docetaxel
- Where
- 20 sites in United States
- Volunteers
- 98 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression
In HIV-infected patients, enhanced PD-1 expression of T cells correlates with T cell depletion, as evidenced by reduced virus-specific proliferative capacity and decreased cytokine expression.Targeting PD-L1 drugs to block…
- Trial name
- NCT05129189
- Testing
- ASC22 group
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Public Health Clinical Center
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is a randomized,Phase III, multicenter ,open-label study designed to evaluate the safety and efficacy of SHR-1210 with carboplatin and pemetrexed versus…
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms
- Trial name
- NCT03134872
- Testing
- SHR-1210, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 419 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
This phase II trial studies the side effects of durvalumab when given together with chemotherapy in treating patients with solid tumors that have spread to other places in the body (advanced).
- Trial name
- NCT03907475
- Testing
- Biopsy Procedure, Biospecimen Collection, Capecitabine
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.
- Trial name
- NCT03312842
- Testing
- CS1001
- Where
- 2 sites in China
- Volunteers
- 259 people
- Sponsor
- CStone Pharmaceuticals
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Phase 2 study to evaluate the clinical activity of INCMGA00012 in patients with Unresectable or metastatic Adenosquamous Pancreatic or Ampullary Cancer.
- Trial name
- NCT04116073
- Testing
- INCMGA00012 (PD-1 antibody)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1…
- Trial name
- NCT03727880
- Testing
- Pembrolizumab, Defactinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lei Zheng
Unresectable Hepatocellular Carcinoma
A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
This study is a multicenter, registered research aimed at evaluating the efficacy of different treatment regimens in the treatment of unresectable CNLC liver cancer stage III hepatocellular carcinoma
- Trial name
- NCT05660213
- Testing
- Targeted drugs combined with anti-PD-1/PD-L1 antibodies, TACE (transarterial chemoembolization) combined with targeted/immunotherapy, Lenvatinib monotherapy
- Volunteers
- 750 people
- Sponsor
- Fudan University
Myelodysplastic Syndromes
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
This is a multicenter, open-label, Phase 1b study of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] monoclonal antibody) in participants who have hypomethylating agent (HMA)-naïve myelodysplastic syndromes (MDS) and…
- Trial name
- NCT02508870
- Testing
- Atezolizumab, Azacitidine
- Where
- 15 sites in United States
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BGB-A333 is a humanized IgG1-variant monoclonal antibody against programmed cell death 1-ligand 1 (PD-L1), the ligand of an immune check point- receptor, programmed cell death-1 (PD-1).
- Trial name
- NCT03379259
- Testing
- BGB-A333, BGB-A317
- Where
- 8 sites in Australia, New Zealand and 1 more
- Volunteers
- 39 people
- Sponsor
- BeiGene
Solid Tumor
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel +…
- Trial name
- NCT02715531
- Testing
- 5-FU, Atezolizumab, Bevacizumab
- Where
- 30 sites in United States, Australia and 5 more
- Volunteers
- 243 people
- Sponsor
- Hoffmann-La Roche
Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )
Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours
Although it is usually described as an immunosuppressive modality and not thought of as immunotherapy, there are new preclinical evidences suggesting that high-dose ionizing irradiation (IR) results in direct tumour cell death…
- Trial name
- SABR-PDL1 (NCT02992912)
- Testing
- Anti-PD-L1 antibody atezolizumab, SABR
- Where
- France
- Volunteers
- 138 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Cancer
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
This open-label, Phase Ib study that has six treatment arms is designed to assess the safety, pharmacology and preliminary efficacy of atezolizumab (MPDL3280A; an engineered anti-programmed death-ligand 1 [PDL1] antibody)…
- Trial name
- NCT01633970
- Testing
- 5-FU, Atezolizumab, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Genentech, Inc.
Advanced Tumors
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of LDP in subjects with advanced malignant tumors.
- Trial name
- NCT03908814
- Testing
- Whole Human Anti-PD-L1 Antibody Injection (LDP)
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma, Biliary Tract Cancer, Extranodal NK T Cell Lymphoma, Nasal
- Trial name
- NCT03999658
- Testing
- STI-3031
- Sponsor
- Sorrento Therapeutics, Inc.
Triple Negative Breast Cancer
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo.
- Trial name
- NCT03281954
- Testing
- Atezolizumab
- Where
- 217 sites in United States, Canada
- Volunteers
- 1,550 people
- Sponsor
- NSABP Foundation Inc